Dr. Christopher Burcham is an AIChE Fellow and an Executive Director in the Synthetic Molecule Design and Development (SMDD) Department at Eli Lilly & Company. Chris leads the Crystallization and Solids Dispersion Engineering Group responsible for the technical oversite and advancement of particle engineering and absorption enabling platforms.  Chris also chairs the Science Advisory Board, responsible for the strategic oversight and review of all external technology initiatives in SMDD.  Chris was the Scientific Team Leader for Reyvow™, responsible for the technical oversight of all aspects of drug substance and drug product development, including process and product development, regulatory registration, and technology transfer into Lilly Manufacturing. Chris has been involved in the development of several products on the market including Humalog®, Humalin®, Effient™, Verzinio®, and most recently Jaypirca®. Chris received his PhD from Princeton University, and his BS from the University of Illinois, both in Chemical Engineering. His career started at The Dow Chemical Company.  In 2002, Chris joined Eli Lilly and soon after moved to development. Chris is the Area 2B Session Chair (Crystallization and Precipitation) and an Adjunct Professor at Strathclyde University. Chris has been recognized with the PD2M Outstanding Contribution to QbD for Drug Substance Award, the Lilly Engineering Excellence Award and the Lilly Research Laboratory President’s Scientific Recognition Award. Chris is very engaged in external research with many partner academic institutions and collaborators, he holds three patents and has more than 50 refereed publications.